Management of hyperprolactinemia in infertility

Journal of Reproductive Medicine for the Obstetrician and Gynecologist

Volumn 44, Issue 12 SUPPL., 1999, Pages 1116-1120

  Crosignani, Pier Giorgio ^a  

^a UNIVERSITY OF MILAN   (Italy)

Author keywords

Cabergoline; Dopamine agonists; Hyperprolactinemia; Infertility, female

Indexed keywords

BROMOCRIPTINE; CABERGOLINE; DIHYDROERGOCRISTINE; DIHYDROERGOCRYPTINE; DOPAMINE RECEPTOR STIMULATING AGENT; GONADORELIN; GONADOTROPIN; HUMAN MENOPAUSAL GONADOTROPIN; LISURIDE; METERGOLINE; PERGOLIDE; PROLACTIN; QUINAGOLIDE; TERGURIDE;

ANOVULATION; ARTICLE; FEMALE INFERTILITY; HUMAN; HYPERPROLACTINEMIA; HYPOPHYSIS ADENOMA; PREGNANCY RATE; PRIORITY JOURNAL; PROLACTIN BLOOD LEVEL; PROLACTINOMA;

ANOVULATION; DOPAMINE AGONISTS; FEMALE; HUMANS; HYPERPROLACTINEMIA; INFERTILITY, FEMALE; PREGNANCY; PREGNANCY COMPLICATIONS; PREGNANCY OUTCOME;

EID: 0033451321     PISSN: 00247758     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (39)

1. Miyai K, Ichihara K, Kondo K, et al: Asymptomatic hyperprolactinaemia and prolactinoma in the general population: Mass screening by paired assays of serum prolactin. Clin Endocrinol 1986;25:549-554
2. Molitch ME: Manifestations, epidemiology and pathogenesis of prolactinomas in women. In Prolactinomas. Edited by JM Olefsky, RJ Robbins. New York, Churchill Livingstone, 1986, pp 67-95
3. Abd El-Hamid MW, Joplin GF, Lewis PD: Incidentally found small pituitary adenomas may have no effect on fertility. Acta Endocrinol 1988;117:361-364
4. Annegers JF, Coulam CB, Abboud CF, et al: Pituitary adenoma in Olmsted County, Minnesota, 1935-1977: A report of an increasing incidence of diagnosis in women of childbearing age. Mayo Clin Proc 1978;53:661-643
5. Futterweit W: Pituitary tumors and polycystic ovarian disease. Obstet Gynecol 1983;62:74S-79S
6. Franks S: Polycystic ovary syndrome: A changing perspective. Clin Endocrinol 1989;31:87-120
7. Crosignani PG, Scarduelli C, Brambilla G, et al: Spontaneous pregnancies in hyperprolactinemic women. Gynecol Obstet Invest 1985;19:17-20
8. Kredenster JV, Hoskins CF, Scott JZ: Hyperprolactinemia: A significant factor in female infertility. Am J Obstet Gynecol 1981;139:264-267
9. Archer DF: Prolactin response to thyrotropin-releasing hormone in women with infertility and/or randomly elevated serum prolactin levels. Fertil Steril 1987;47:559-564
10. Farkouh NH, Packer MG, Frantz AG: Large molecular PRL with reduced receptor activity in human serum: High proportion in basal state and reduced after TRH. J Clin Endocrinol Metab 1979;48:1026-1032
11. Ferrari C, Rampini P, Benco R, et al: Functional characterization of hypothalamic hyperprolactinemia. J Clin Endocrinol Metab 1982;55:897-901
12. Ferrari C, Crosignani PG: Hypothalamic disease presenting as amenorrhoea: Value of computed tomography. Br J Obstet Gynaecol 1985;92:1251-1257
13. Crosignani PG, Ferrari C, Scarduelli C, et al: Dynamic functional testing in hyperprolactinemic disorders. In Pituitary Hyperfunction: Physiopathology and Clinical Aspects. Edited by F Camanni, EE Muller. New York, Raven Press, 1984, pp 321-331
14. Blackwell RE: Hyperprolactinemia: Evaluation and management. Endocrinol Metab Clin North Am 1992;21:105-124
15. Magyar DM, Marshall JR: Pituitary tumors and pregnancy. Am J Obstet Gynecol 1978;132:739-751
16. Vance ML, Evans WS, Thorner MO: Drugs five years later: Bromocriptine. Ann Intern Med 1984;100:78-91
17. Weil C: The safety of bromocriptine in hyperprolactinaemic female infertility: A literature review. Curr Med Res Opin 1986;10:172-195
18. Robbins RJ: Medical management of prolactinomas. In Prolactinomas. Edited by JM Olefsky, RJ Robbins. New York, Churchill Livingstone. 1986, pp 97-114
19. Bevan JS, Burke CW: Perfusion studies of bromocriptine-treated and untreated macroprolactinomas: Effects of dopamine, bromocriptine and TRH. Clin Endocrinol 1989; 30:667-680
20. Pellegrini I, Rasolonjanahary R, Gunz G, et al: Resistance to bromocriptine in prolactinomas. J Clin Endocrinol Metab 1989;69:500-509
21. Diamant YZ, Yarkoni S, Evron S: Combined clomiphenebromocriptine treatment in anovulatory, oligomenorrheic and hyperprolactinemic women resistant to separate clomiphene or bromocriptine regimens. Infertility 1980;3: 11-16
22. Ferrari C, Barbieri C, Caldara R, et al: Long-lasting prolactin-lowering effect of cabergoline, a new dopamine agonist, in hyperprolactinemic patients. J Clin Endocrinol Metab 1986;63:941-945
23. Mattei AM, Ferrari C, Baroldi P, et al: Prolactin-lowering effect of acute and once weekly repetitive oral administration of cabergoline at two dose levels in hyperprolactinemic patients. J Clin Endocrinol Metab 1988;66:193-198
24. Krupp P, Turkalj I: Surveillance of Parlodel (bromocriptine) in pregnancy and offspring. In Prolactinomas and Pregnancy. Edited by HS Jacobs. Lancaster Pennsylvania, MTP Press, 1984, pp 45-50
25. Robert E, Musatti L, Piscitelli G, et al: Pregnancy outcome after treatment with the ergot derivate, cabergoline. Reprod Toxicol 1996;10:333-337
26. Miyakawa I, Taniyama K, Koike H, et al: Successful pregnancy in an acromegalic patient during 2-Br-a-ergocryptine (CB-154) therapy. Acta Endocrinol 1982;101:333-338
27. Gemzell C, Wang CF: Outcome of pregnancy in women with pituitary adenoma. Fertil Steril 1979;31:363-372
28. Molitch ME: Pregnancy and the hyperprolactinemic woman. N Engl J Med 1985;312:1364-1370
29. Konopka P, Raymond JP, Merceron RE, et al: Continuous administration of bromocriptine in the prevention of neurological complications in pregnant women with prolactinomas. Am J Obstet Gynecol 1983;146:935-938
30. Bergh T, Nillius SJ, Enoksson P, et al: Bromocriptine-induced regression of a suprasellar extending prolactinoma during pregnancy. J Endocrinol Invest 1984;7:133-136
31. Crosignani PG, Ferrari C, Mattei AM: Visual field defects and reduced visual acuity during pregnancy in two patients with prolactinoma: Rapid regression of symptoms under bromocriptine. Br J Obstet Gynaecol 1984;91:821-823
32. Tan SL, Jacobs HS: Rapid regression through bromocriptine therapy of a suprasellar extending prolactinoma during pregnancy. Int J Gynaecol Obstet 1986;24:209-215
33. Mornex R, Orgiazzi J, Hugues B, et al: Normal pregnancies after treatment of hyperprolactinemia with bromoergocryptine, despite suspected pituitary tumors. J Clin Endocrinol Metab 1978;47:290-295
34. Bergh T, Nillius SJ, Larsson S-G, et al: Effects of bromocriptine-induced pregnancy on prolactin-secreting pituitary tumours. Acta Endocrinol 1981;98;333-338
35. Crosignani PG, Ferrari C, Scardeulli C, et al: Spontaneous and induced pregnancies in hyperprolactinemic women. Obstet Gynecol 1981;58:708-713
36. Andersen AN, Starup J, Tabor A, et al: The possible prognostic value of serum prolactin increment during pregnancy in hyperprolactinaemic patients. Acta Endocrinol 1983;102: 1-5
37. Daya S, Shewchuk AB, Brycelond N: The effect of multiparity on intrasellar prolactinomas. Am J Obstet Gynecol 1984;148:512-515
38. Crosignani PG, Mattei AM, Scarduelli C, et al: Is pregnancy the best treatment for hyperprolactinemia? Hum Reprod 1989;4:910-912
39. Musey VC, Collina DC, Musey PI et al: Long-term effect of a first pregnancy on the secretion of prolactin. N Engl J Med 1987;316:229-234